Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain

被引:177
作者
Harigaya, Y
Saido, TC
Eckman, CB
Prada, CM
Shoji, M
Younkin, SG
机构
[1] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[2] Gunma Univ, Sch Med, Dept Neurol, Maebashi, Gumma 3718511, Japan
[3] RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 35101, Japan
关键词
Alzheimer's disease; amyloid beta protein; enzyme-linked immunosorbent assay; pyroglutamate; senile plaques;
D O I
10.1006/bbrc.2000.3490
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The amyloid beta protein (A beta) deposited in the Alzheimer's disease (AD) brain is heterogeneous at both its amino and carboxyl termini. Recent studies of the genetic forms of AD indicate that the aggregation and deposition of A beta 42 may be a common initiating event in all forms of AD. Here, we analyzed the amino termini of the A beta species deposited in the AD brain, focusing specifically on species with amino-terminal pyroglutamate at position 3 (A beta 3(pE)). Immunocytochemical analysis of AD brains with an antibody specific for A beta 3(pE) confirmed that these species deposit in blood vessels and senile plaques. Using specific sandwich ELISAs, we determined the amounts of A beta 3(pE)-40 and A beta 3(pE)-42(43) in AD brain compared with other forms. This analysis showed that A beta 3(pE)-40 is closely correlated with the extent of A beta deposition in blood vessels, whereas A beta 3(pE)-42(43) is not. In addition, A beta 3(pE)-42(43) is an important component of the A beta deposited in senile plaques of the AD brain, constituting approximately 25% of the total A beta 42(43). In vitro comparison of A beta 1-42 and A beta 3(pE)-42 showed that A beta 3(pE)-42 is highly prone to oligomerization. These findings suggest that A beta 3(pE)-42 may be particularly important in AD pathogenesis. (C) 2000 Academic Press.
引用
收藏
页码:422 / 427
页数:6
相关论文
共 32 条
[1]   Familial Alzheimer's disease-linked presenilin 1 variants elevate A beta 1-42/1-40 ratio in vitro and in vivo [J].
Borchelt, DR ;
Thinakaran, G ;
Eckman, CB ;
Lee, MK ;
Davenport, F ;
Ratovitsky, T ;
Prada, CM ;
Kim, G ;
Seekins, S ;
Yager, D ;
Slunt, HH ;
Wang, R ;
Seeger, M ;
Levey, AI ;
Gandy, SE ;
Copeland, NG ;
Jenkins, NA ;
Price, DL ;
Younkin, SG .
NEURON, 1996, 17 (05) :1005-1013
[2]   RELEASE OF EXCESS AMYLOID BETA-PROTEIN FROM A MUTANT AMYLOID BETA-PROTEIN PRECURSOR [J].
CAI, XD ;
GOLDE, TE ;
YOUNKIN, SG .
SCIENCE, 1993, 259 (5094) :514-516
[3]   Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [J].
Citron, M ;
Westaway, D ;
Xia, WM ;
Carlson, G ;
Diehl, T ;
Levesque, G ;
JohnsonWood, K ;
Lee, M ;
Seubert, P ;
Davis, A ;
Kholodenko, D ;
Motter, R ;
Sherrington, R ;
Perry, B ;
Yao, H ;
Strome, R ;
Lieberburg, I ;
Rommens, J ;
Kim, S ;
Schenk, D ;
Fraser, P ;
Hyslop, PS ;
Selkoe, DJ .
NATURE MEDICINE, 1997, 3 (01) :67-72
[4]   MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION [J].
CITRON, M ;
OLTERSDORF, T ;
HAASS, C ;
MCCONLOGUE, L ;
HUNG, AY ;
SEUBERT, P ;
VIGOPELFREY, C ;
LIEBERBURG, I ;
SELKOE, DJ .
NATURE, 1992, 360 (6405) :672-674
[5]   Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1 [J].
Duff, K ;
Eckman, C ;
Zehr, C ;
Yu, X ;
Prada, CM ;
Pereztur, J ;
Hutton, M ;
Buee, L ;
Harigaya, Y ;
Yager, D ;
Morgan, D ;
Gordon, MN ;
Holcomb, L ;
Refolo, L ;
Zenk, B ;
Hardy, J ;
Younkin, S .
NATURE, 1996, 383 (6602) :710-713
[6]   ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J].
GLENNER, GG ;
WONG, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) :885-890
[7]   AMYLOID-BETA PROTEIN (A-BETA) IN ALZHEIMERS-DISEASE BRAIN - BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A-BETA-40 OR A-BETA-42(43) [J].
GRAVINA, SA ;
HO, LB ;
ECKMAN, CB ;
LONG, KE ;
OTVOS, L ;
YOUNKIN, LH ;
SUZUKI, N ;
YOUNKIN, SG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (13) :7013-7016
[8]   MODIFIED AMYLOID-BETA PROTEIN ENDING AT 42 OR 40 WITH DIFFERENT SOLUBILITY ACCUMULATES IN THE BRAIN OF ALZHEIMERS-DISEASE [J].
HARIGAYA, Y ;
SHOJI, M ;
KAWARABAYASHI, T ;
KANAI, M ;
NAKAMURA, T ;
IIZUKA, T ;
IGETA, Y ;
SAIDO, TC ;
SAHARA, N ;
MORI, H ;
HIRAI, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (03) :1015-1022
[9]   Quantification of modified amyloid β peptides in Alzheimer disease and Down syndrome brains [J].
Hosoda, R ;
Saido, TC ;
Otvos, L ;
Arai, T ;
Mann, DMA ;
Lee, VMY ;
Trojanowski, JQ ;
Iwatsubo, T .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (11) :1089-1095
[10]   VISUALIZATION OF A-BETA-42(43) AND A-BETA-40 IN SENILE PLAQUES WITH END-SPECIFIC A-BETA MONOCLONALS - EVIDENCE THAT AN INITIALLY DEPOSITED SPECIES IS A-BETA-42(43) [J].
IWATSUBO, T ;
ODAKA, A ;
SUZUKI, N ;
MIZUSAWA, H ;
NUKINA, N ;
IHARA, Y .
NEURON, 1994, 13 (01) :45-53